Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trial.

ABSTRACT:

Rationale

Most studies evaluating the safety and tolerability of intranasal oxytocin (OT) have not reported consistent adverse events (AEs), but they have largely focused on young men and single-dose administration. Thus, it is unclear whether these findings translate to older individuals and with longer administration periods.

Objective

Extending previous work, this study investigated the safety and tolerability of chronic intranasal OT in generally healthy older men.

Methods

Data were from a randomized, placebo (P)-controlled, double-blind clinical trial evaluating the effects of 4 weeks of self-administered intranasal OT (24 IU twice daily) in older adults with no major physical or cognitive impairments. Heart rate, blood pressure, urine osmolality, and serum metab

SUBMITTER: Rung JM 

PROVIDER: S-EPMC8115997 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature